A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects
The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).
Castration-Resistant Prostate Cancer
DRUG: SHR3680 tablets
Delta QTc Fridericia (QTcF), Mean change from baseline in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake., Day -1 and Day 1 and Day 17|Concentration-delta QTcF relationship, Relationship between SHR3680 plasma concentration and delta QTcF based on linear-mixed effect model., Day -1 and Day 1 and Day 17
Electrocardiographic parameters Delta PR, A change from time-matched baseline measurements in PR interval will be determined on Day -1, Day 1 and Day 17., Day -1 and Day 1 and Day 17|Electrocardiographic parameters Delta RR, A change from time-matched baseline measurements in RR interval will be determined on Day -1, Day 1 and Day 17., Day -1 and Day 1 and Day 17|Electrocardiographic parameters Delta QRS, A change from time-matched baseline measurements in QRS interval will be determined on Day -1, Day 1 and Day 17., Day -1 and Day 1 and Day 17|Electrocardiographic parameters Delta QTc Bazett (QTcB), Mean change from baseline in QTcB as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake., Day -1 and Day 1 and Day 17|Electrocardiographic parameters T-wave morphology, Number and percentage of participants with changes from baseline, Day -1 and Day 1 and Day 17|Electrocardiographic parameters U-wave morphology, Number and percentage of participants with changes from baseline, Day -1 and Day 1 and Day 17|Incidence and severity of AE/SAE/AESI (rated based on CTCAE v5.0), Participants will be monitored for safety during the Screening and Treatment Phases, and up to 30 days after the last dose of study drug. From the end of treatment phase onward collection of AE will be limited to Grade 3 or higher, all SAE and AESI from the remainder of the study., Day-1, Day 1 to Day 18|Pharmacokinetic parameter area under the plasma drug concentration-time curve (AUC) from time 0 to 24 hours, Day 1-2 and Day 17-18|Pharmacokinetic parameter maximum concentration observed (Cmax), Day 1-2 and Day 17-18|Pharmacokinetic parameter time to reach Cmax (tmax), Day 1-2 and Day 17-18|Pharmacokinetic parameter minimum observed plasma concentration at steady-state (Cmin,ss), Cmin,ss will only be collected on Day 17|Pharmacokinetic parameter accumulation ratio（Rac）, Day 1-2 and Day 17-18
The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).